Suchergebnisse - "PARP inhibitor"

PubPharm (2.849)

51

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy

enthalten in: Advances in therapy | 2024

von Rognoni, C. | Lorusso, D. | Costa, F. | +1

52

Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor

enthalten in: Japanese journal of clinical oncology | 2024

von Akahira, R. | Fukuda, K. | Shimazu, K. | +5

53

Germline BRCA2 variant with low variant allele frequency detected in tumor-only comprehensive genomic profiling

enthalten in: Cancer science | 2024

von Hayashi, H. | Kunimasa, K. | Tanishima, S. | +6

54

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

enthalten in: Cell & bioscience | 2024

von Sorrin, A. | Dasgupta, A. | McNaughton, K. | +5

55

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo : Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

enthalten in: Gynecologic oncology | 2024

von Pothuri, B. | Han, S. | Chase, D. | +23

56

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

enthalten in: Cell & bioscience | 2024

von Sorrin, A. | Dasgupta, A. | McNaughton, K. | +5

57

PARP1 roles in DNA repair and DNA replication : The basi(c)s of PARP inhibitor efficacy and resistance

enthalten in: Seminars in oncology | 2024

von Kanev, P. | Atemin, A. | Stoynov, S. | +1

58

BRCA1/2 reversion mutations in a pan-cancer cohort

enthalten in: Cancer science | 2024

von Nakamura, K. | Hayashi, H. | Kawano, R. | +20

59

Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer

enthalten in: Critical reviews in oncology/hematology | 2024

von Bao, W. | Li, Z.

60

Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects

enthalten in: Investigational new drugs | 2024

von Kim, H. | Yang, E. | Lee, S. | +7